Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

73.23
+2.283.21%
Pre-market: 72.00-1.2300-1.68%09:12 EDT
Volume:817.02K
Turnover:59.51M
Market Cap:7.73B
PE:59.54
High:73.57
Open:71.66
Low:70.08
Close:70.95
Loading ...

Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?

Zacks
·
Yesterday

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

THOMSON REUTERS
·
Yesterday

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

Business Wire
·
Yesterday

3 Healthcare Stocks That Concern Us

StockStory
·
28 Apr

Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)

TIPRANKS
·
25 Apr

3 Growth Companies With High Insider Ownership Achieving 70% Earnings Growth

Simply Wall St.
·
24 Apr

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Insider Monkey
·
24 Apr

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

Business Wire
·
23 Apr

BRIEF-Diabetes Care Publishes Results From Prevalence Phase Of Corcept’S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Reuters
·
21 Apr

Diabetes Care Publishes Results From Prevalence Phase of Corcept’s Catalyst Trial in People With Difficult-to-Control Type 2 Diabetes

THOMSON REUTERS
·
21 Apr

Analysts’ Top Healthcare Picks: Merus (MRUS), Corcept Therapeutics (CORT)

TIPRANKS
·
17 Apr

Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter

Simply Wall St.
·
10 Apr

BRIEF-Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab

Reuters
·
07 Apr

Corcept Therapeutics Inc - Bella Trial to Enroll 90 Women With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
07 Apr

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Business Wire
·
07 Apr

Corcept Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
03 Apr

Form 4 | CORCEPT THERAPEUTICS INC Officer Joseph Douglas Lyon sold 200,650 Shares.

Filings Track
·
03 Apr

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Zacks
·
03 Apr

Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?

Zacks
·
02 Apr

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

Zacks
·
02 Apr